Shanghai Rendu (China) Top Management
| 688193 Stock | 52.70 1.53 2.99% |
Shanghai Rendu employs about 335 people. The company is managed by 7 executives with a total tenure of roughly 782 years, averaging almost 111.0 years of service per executive, having 47.86 employees per reported executive. Reviewing how management performs at Shanghai Rendu Biotechnology provides context around adaptability, decision quality, and the consistency of business execution. Used properly, management analysis helps separate durable execution from results that may only reflect a supportive market cycle.
| Minghui Yu Director GM Director |
| Tingjiang Cai CFO CFO Supervisor |
Shanghai |
Management Team Effectiveness
The company has return on total asset (ROA) of -1.94 % which suggests that the asset base is not productive at current operating levels. This is extremely low compared to the sector. Similarly, it shows a return on equity (ROE) of -0.59 %, which implies that returns to shareholders were negative during the period.Outstanding Bonds
Reviewing Shanghai Rendu Biotechnology bond obligations helps investors understand how much of the business is financed with fixed-income capital rather than purely with equity. Longer-dated obligations can improve financing stability, but they also leave investors more exposed if the underlying business weakens before the debt matures.
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Holders Distribution
Institutional ownership analysis for Shanghai Rendu Biotechnology matters because banks, hedge funds, pension plans, and other professional investors can influence price and liquidity more forcefully than smaller holders. The opportunity for retail investors is not to imitate blindly, but to understand how large-holder positioning may affect liquidity, volatility, and timing.
Workforce Comparison
Shanghai Rendu Biotechnology ranks first in number of employees among leading competitors. The total workforce of Health Care industry is presently estimated at about 9,258. Shanghai Rendu holds roughly 335 in number of employees claiming about 4% of equities under Health Care sector.
The company has Profit Margin (PM) of -3.0 %, which implies that the company is generating losses at the net margin level. This is extremely low compared to the sector. Similarly, it shows Operating Margin (OM) of 17.0 %, which means that the company is generating $17.0 of operating income per $100 of sales. Benchmark Summation
Operator |
This analysis covers sixty-one data points across the selected time horizon. Shanghai Rendu Price Series Summation is a cross summation of Shanghai Rendu price series and its benchmark/peer.
Notable Stakeholders
Stakeholder analysis for Shanghai Rendu is useful because companies often face trade-offs among groups that want very different outcomes from the same business. The practical value is that investors can see where interests align, where they conflict, and how that tension could influence execution.
| Tingjiang Cai | CFO Supervisor | Profile | |
| Minghui Yu | GM Director | Profile | |
| Chang Zhang | Registration Director | Profile | |
| Ruohua Cao | Deputy Director | Profile | |
| Feng Zhou | Deputy Instrumentation | Profile | |
| Ho Kim | Deputy Instrumentation | Profile | |
| Zhenling Cui | Senior RD | Profile |
Management Information & Data Sources
Shanghai Rendu is a mid-cap company in Biotech. Executive review focuses on insiders, senior management, and employee signals. Changes in insider ownership can offer context, but they should be read with fundamentals and market conditions. Shanghai Rendu employs 335 people.
For Shanghai Rendu Biotechnology, this section uses periodic company reporting and market reference feeds with Macroaxis normalization rules applied to keep cross-asset comparisons consistent. Intraday timing differences may exist. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Ellen Johnson - Member of Macroaxis Editorial BoardWorkforce Efficiency and Productivity
Investors reviewing Shanghai Rendu Biotechnology can use workforce efficiency as another lens on execution, especially when comparing similar businesses in the same industry. This is most informative when investors want to connect operating scale with efficiency rather than reviewing headcount in isolation.
Shanghai Rendu Manpower Efficiency
Return on Shanghai Rendu Manpower
| Revenue Per Employee | 529.4K | |
| Revenue Per Executive | 25.3M | |
| Net Loss Per Employee | 23.3K | |
| Net Loss Per Executive | 1.1M | |
| Working Capital Per Employee | 2.4M | |
| Working Capital Per Executive | 115.8M |
Popular Tools for Shanghai Stock analysis
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |